The Management of Treatment-Experienced HIV-Infected Patients: New Drugs and Drug Combinations
dc.contributor.author | Wilson, Lucy E. | |
dc.contributor.author | Gallant, Joel E. | |
dc.contributor.author | Mayer, Kenneth H. | |
dc.date.accessioned | 2023-08-04T18:54:09Z | |
dc.date.available | 2023-08-04T18:54:09Z | |
dc.date.issued | 2009-01-15 | |
dc.description.abstract | The recent availability of new antiretroviral agents for the treatment of human immunodeficiency virus (HIV) infection has increased treatment options and has improved the durability, tolerability, and long-term efficacy of antiretroviral therapy, even among patients with extensive treatment experience and high levels of drug resistance. This expansion of therapeutic options has led to a revision of current treatment guidelines, which now state that the goal of antiretroviral therapy in all patients is suppression of the plasma HIV RNA level to <50 copies/mL. Successful management of infection for treatment-experienced patients with the new agents requires an understanding of their pharmacology and resistance patterns and the appropriate use of laboratory testing to optimize regimen selection. This review discusses the use of recently approved antiretroviral agents in the management of HIV infection in treatment-experienced patients. | en_US |
dc.description.sponsorship | Johns Hopkins University has received grant support from Gilead Sciences, Merck, Pfizer, Roche, and Tibotec for research conducted by J.G. | en_US |
dc.description.uri | https://academic.oup.com/cid/article/48/2/214/305414 | en_US |
dc.format.extent | 8 pages | en_US |
dc.genre | journal articles | en_US |
dc.identifier | doi:10.13016/m2kdr1-l2st | |
dc.identifier.citation | Lucy E. Wilson and others, The Management of Treatment-Experienced HIV-Infected Patients: New Drugs and Drug Combinations, Clinical Infectious Diseases, Volume 48, Issue 2, 15 January 2009, Pages 214–221, https://doi.org/10.1086/595701 | en_US |
dc.identifier.uri | https://doi.org/10.1086/595701 | |
dc.identifier.uri | http://hdl.handle.net/11603/29088 | |
dc.language.iso | en_US | en_US |
dc.publisher | Oxford University Press | en_US |
dc.relation.isAvailableAt | The University of Maryland, Baltimore County (UMBC) | |
dc.relation.ispartof | UMBC Emergency Health Services Department Collection | |
dc.relation.ispartof | UMBC School of Public Policy | |
dc.relation.ispartof | A. All Hilltop Institute (UMBC) Works | |
dc.rights | This item is likely protected under Title 17 of the U.S. Copyright Law. Unless on a Creative Commons license, for uses protected by Copyright Law, contact the copyright holder or the author. | en_US |
dc.subject | hiv | en_US |
dc.subject | drug resistance | en_US |
dc.subject | drug combinations | en_US |
dc.subject | antiretroviral agents | en_US |
dc.title | The Management of Treatment-Experienced HIV-Infected Patients: New Drugs and Drug Combinations | en_US |
dc.type | Text | en_US |
Files
License bundle
1 - 1 of 1
Loading...
- Name:
- license.txt
- Size:
- 2.56 KB
- Format:
- Item-specific license agreed upon to submission
- Description: